Pulmonary complications often fatal in systemic JIA

November 19, 2012
Pulmonary complications often fatal in systemic JIA
Pulmonary complications are under-recognized in systemic juvenile idiopathic arthritis, and are often fatal, according to a study published online Nov. 8 in Arthritis Care & Research.

(HealthDay)—Pulmonary complications are under-recognized in systemic juvenile idiopathic arthritis (sJIA), and are often fatal, according to a study published online Nov. 8 in Arthritis Care & Research.

Yukiko Kimura, M.D., from the Hackensack University Medical Center in New Jersey, and colleagues utilized an electronic listserv to identify sJIA patients who developed pulmonary artery hypertension (PAH), interstitial lung disease (ILD), and/or alveolar proteinosis (AP). The 25 patients were compared to a sJIA cohort of patients from the Childhood and Rheumatology Research Alliance (CARRA; 389 participants).

The researchers found that, compared with the CARRA cohort, patients were significantly more likely to be female; have more systemic features; and to have been exposed to an interleukin-1 (IL-1) inhibitor, tocilizumab, infliximab, corticosteroids, intravenous immunoglobulin, cyclosporine, and cyclophosphamide. During the course of their disease, 80 percent of the patients had macrophage activation syndrome (MAS), and 60 percent had MAS at pulmonary diagnosis. PAH was seen in 16 patients, ILD in seven, and AP in five patients. At pulmonary symptom onset, 68 percent of patients were taking or recently (one month or less) discontinued a biologic agent and 48 percent were taking anti-IL-1 therapy. At a mean of 8.8 months following pulmonary diagnosis, 68 percent of died.

"PAH, AP and ILD are under-recognized of sJIA which are frequently fatal," the authors write. "These may be the result of severe uncontrolled systemic disease activity, and may be influenced by medication exposure."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Not all juvenile arthritis is the same

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Not all juvenile arthritis is the same

October 22, 2012
Systemic juvenile idiopathic arthritis (SJIA) is currently classified as a subtype of juvenile idiopathic arthritis but with the addition of systemic inflammation often resulting in fever, rash and serositis. New research ...

Standardized treatment plans developed for new-onset JIA

July 3, 2012
(HealthDay) -- Four standardized consensus treatment plans (CTPs) have been developed for patients with new-onset systemic juvenile idiopathic arthritis (JIA), according to research published in the July issue of Arthritis ...

Pulmonary hypertension combination therapy may lead to greater disease burden

October 22, 2012
Patients with pulmonary arterial hypertension (PAH) receiving combination therapy with intravenous (IV) PGI2 may suffer from greater disease burden compared with those receiving monotherapy or combination therapy, excluding ...

New study may lead to quicker diagnosis, improved treatment for fatal lung disease

July 11, 2011
One-fifth of all patients with pulmonary arterial hypertension suffer with the fatal disease for more than two years before being correctly diagnosed and properly treated, according to a new national study led by researchers ...

Systemic sclerosis complications more severe in African Americans than Caucasians

May 10, 2012
African Americans have more severe complications from systemic sclerosis, also known as scleroderma, than Caucasians. Findings published today in, Arthritis & Rheumatism, a journal of the American College of Rheumatology ...

Statins may increase risk of interstitial lung abnormalities in smokers

January 6, 2012
Use of statins may influence susceptibility to or the progression of interstitial lung disease (ILD) in smokers, according to a new study.

Recommended for you

Fluid in the knee holds clues for why osteoarthritis is more common in females

June 26, 2017
Researchers have more evidence that males and females are different, this time in the fluid that helps protect the cartilage in their knee joints.

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Drug for refractory psoriatic arthritis shows promise in clinical trial

May 24, 2017
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Cross-species links identified for osteoarthritis

May 17, 2017
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

Osteoarthritis could be prevented with good diet and exercise

May 12, 2017
Osteoarthritis can potentially be prevented with a good diet and regular exercise, a new expert review published in the Nature Reviews Rheumatology reports.

Rodents with trouble walking reveal potential treatment approach for most common joint disease

May 11, 2017
Maintaining the supply of a molecule that helps to nourish cartilage prevented osteoarthritis in animal models of the disease, according to a report published in Nature Communications online May 11.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.